Department of Medical Ultrasound, The First People's Hospital of Foshan, No. 81 Lingnan Avenue North, Foshan, 528010, China.
BMC Cancer. 2024 Apr 5;24(1):422. doi: 10.1186/s12885-024-12210-z.
As comprehensive surgical management for gastric cancer becomes increasingly specialized and standardized, the precise differentiation between ≤T1 and ≥T2 gastric cancer before endoscopic intervention holds paramount clinical significance.
To evaluate the diagnostic efficacy of contrast-enhanced gastric ultrasonography in differentiating ≤T1 and ≥T2 gastric cancer.
PubMed, Web of Science, and Medline were searched to collect studies published from January 1, 2000 to March 16, 2023 on the efficacy of either double contrast-enhanced gastric ultrasonography (D-CEGUS) or oral contrast-enhanced gastric ultrasonography (O-CEGUS) in determining T-stage in gastric cancer. The articles were selected according to specified inclusion and exclusion criteria, and the quality of the included literature was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 scale. Meta-analysis was performed using Stata 12 software with data from the 2 × 2 crosslinked tables in the included literature.
In total, 11 papers with 1124 patients were included in the O-CEGUS analysis, which revealed a combined sensitivity of 0.822 (95% confidence interval [CI] = 0.753-0.875), combined specificity of 0.964 (95% CI = 0.925-0.983), and area under the summary receiver operating characteristic (sROC) curve (AUC) of 0.92 (95% CI = 0.89-0.94). In addition, five studies involving 536 patients were included in the D-CEGUS analysis, which gave a combined sensitivity of 0.733 (95% CI = 0.550-0.860), combined specificity of 0.982 (95% CI = 0.936-0.995), and AUC of 0.93 (95% CI = 0.91-0.95). According to the I and P values of the forest plot, there was obvious heterogeneity in the combined specificities of the included papers. Therefore, the two studies with the lowest specificities were excluded from the O-CEGUS and D-CEGUS analyses, which eliminated the heterogeneity among the remaining literature. Consequently, the combined sensitivity and specificity of the remaining studies were 0.794 (95% CI = 0.710-0.859) and 0.976 (95% CI = 0.962-0.985), respectively, for the O-CEDUS studies and 0.765 (95% CI = 0.543-0.899) and 0.986 (95% CI = 0.967-0.994), respectively, for the D-CEGUS studies. The AUCs were 0.98 and 0.99 for O-CEGUS and D-CEGUS studies, respectively.
Both O-CEGUS and D-CEGUS can differentiate ≤T1 gastric cancer from ≥T2 gastric cancer, thus assisting the formulation of clinical treatment strategies for patients with very early gastric cancer. Given its simplicity and cost-effectiveness, O-CEGUS is often favored as a staging method for gastric cancer prior to endoscopic intervention.
随着胃癌综合外科治疗日益专业化和规范化,内镜干预前准确区分 T1 期和 T2 期以上胃癌具有重要的临床意义。
评估对比增强超声胃镜在区分 T1 期和 T2 期以上胃癌中的诊断效能。
检索 2000 年 1 月 1 日至 2023 年 3 月 16 日期间在 Pubmed、Web of Science 和 Medline 上发表的关于双对比增强超声胃镜(D-CEGUS)或口服对比增强超声胃镜(O-CEGUS)在确定胃癌 T 分期方面的疗效的研究。根据具体的纳入和排除标准选择文章,并使用 Quality Assessment of Diagnostic Accuracy Studies-2 量表评估纳入文献的质量。使用 Stata 12 软件对纳入文献的 2×2 交叉表中的数据进行 Meta 分析。
共纳入 11 篇文献的 1124 例患者进行 O-CEGUS 分析,其合并敏感性为 0.822(95%置信区间[CI]:0.753-0.875),合并特异性为 0.964(95%CI:0.925-0.983),综合受试者工作特征(sROC)曲线下面积(AUC)为 0.92(95%CI:0.89-0.94)。此外,纳入了 5 项涉及 536 例患者的研究进行 D-CEGUS 分析,其合并敏感性为 0.733(95%CI:0.550-0.860),合并特异性为 0.982(95%CI:0.936-0.995),AUC 为 0.93(95%CI:0.91-0.95)。根据森林图的 I ²和 P 值,纳入文献的合并特异性存在明显异质性。因此,将 O-CEGUS 和 D-CEGUS 分析中特异性最低的两项研究排除后,消除了其余文献之间的异质性。因此,其余研究的合并敏感性和特异性分别为 0.794(95%CI:0.710-0.859)和 0.976(95%CI:0.962-0.985),用于 O-CEDUS 研究和 0.765(95%CI:0.543-0.899)和 0.986(95%CI:0.967-0.994),用于 D-CEGUS 研究。O-CEGUS 和 D-CEGUS 的 AUC 分别为 0.98 和 0.99。
O-CEGUS 和 D-CEGUS 均可区分 T1 期胃癌和 T2 期以上胃癌,有助于制定非常早期胃癌患者的临床治疗策略。鉴于其简单性和成本效益,O-CEGUS 通常更适合作为内镜干预前胃癌的分期方法。